JO3594B1 - تركيبة صيدلانية جديدة - Google Patents

تركيبة صيدلانية جديدة

Info

Publication number
JO3594B1
JO3594B1 JOP/2011/0385A JOP20110385A JO3594B1 JO 3594 B1 JO3594 B1 JO 3594B1 JO P20110385 A JOP20110385 A JO P20110385A JO 3594 B1 JO3594 B1 JO 3594B1
Authority
JO
Jordan
Prior art keywords
novel pharmaceutical
pharmaceutical composition
dimethyl
trioxo
pyrido
Prior art date
Application number
JOP/2011/0385A
Other languages
English (en)
Inventor
Wang Lihong
J Demarini Douglas
T Le Ngocdiep
Henriquez Francisco
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3594(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3594B1 publication Critical patent/JO3594B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يكشف ذلك الاختراع عن تركيبات صيدلانية جديدة تحتوي على ذوابة N-{3-[3- سيكلو بروبيل -5-(2- فلورو -4- يودو - فينيل أمينو)-6، 8- داي ميثيل -2، 4، 7- تراي أوكسو -3، 4، 6، 7- تترا هيدرو- 2H- بيريدو [4، 3-d] بيريميدين -1-يل] فينيل} أسيتاميد داي ميثيل سلفوكسيد، وطرق استخدام التركيبات في علاج و عمليات لتحضيرها.
JOP/2011/0385A 2010-12-20 2011-12-18 تركيبة صيدلانية جديدة JO3594B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
JO3594B1 true JO3594B1 (ar) 2020-07-05

Family

ID=46314827

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0385A JO3594B1 (ar) 2010-12-20 2011-12-18 تركيبة صيدلانية جديدة

Country Status (37)

Country Link
US (5) US20130266649A1 (ar)
EP (4) EP4159204B1 (ar)
JP (2) JP6126014B2 (ar)
KR (1) KR101911109B1 (ar)
CN (1) CN103998041B (ar)
AR (2) AR084102A1 (ar)
AU (1) AU2011349422B2 (ar)
BR (1) BR112013015602B1 (ar)
CA (1) CA2822701C (ar)
CL (1) CL2013001779A1 (ar)
CR (1) CR20130352A (ar)
CY (1) CY1123376T1 (ar)
DK (3) DK4159205T3 (ar)
DO (1) DOP2013000138A (ar)
EA (1) EA025198B1 (ar)
ES (2) ES2820536T3 (ar)
FI (2) FI4159205T3 (ar)
HR (3) HRP20240564T1 (ar)
HU (3) HUE050788T2 (ar)
IL (1) IL226855A (ar)
JO (1) JO3594B1 (ar)
LT (3) LT2654736T (ar)
MA (1) MA34883B1 (ar)
MX (1) MX2013007073A (ar)
MY (1) MY170501A (ar)
NZ (1) NZ612157A (ar)
PE (1) PE20140040A1 (ar)
PL (3) PL2654736T3 (ar)
PT (3) PT4159204T (ar)
RS (2) RS65497B1 (ar)
SG (1) SG191054A1 (ar)
SI (3) SI2654736T1 (ar)
TW (1) TWI505828B (ar)
UA (1) UA113158C2 (ar)
UY (1) UY33818A (ar)
WO (1) WO2012088033A2 (ar)
ZA (1) ZA201304189B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500582UA (en) 2012-08-17 2015-04-29 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
CA2891346A1 (en) * 2012-11-30 2014-06-05 Gossett Campbell Pharmaceutical composition comprising trametinib dimethyl sulfoxide
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
BR112019002007B1 (pt) * 2016-08-10 2024-01-16 F. Hoffmann-La Roche Ag Composição farmacêutica e uso de uma composição farmacêutica
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
US10709699B2 (en) 2016-11-25 2020-07-14 Jiangsu Hengrui Medicine Co., Ltd. Pyridone derivative pharmaceutical composition and preparation method thereof
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
AU2020311942A1 (en) 2019-07-11 2022-02-24 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANCER IN DOGS
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
DE602005004286T2 (de) 2004-06-11 2009-01-02 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2008048469A2 (en) * 2006-10-13 2008-04-24 Actavis Group Pct Hf Controlled-release coated dosage forms containing galantamine
EP2086518A2 (en) * 2006-11-09 2009-08-12 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
RU2470641C2 (ru) * 2007-09-25 2012-12-27 Тева Фармасьютикал Индастриес Лтд. Стабильные составы иматиниба
JP5719770B2 (ja) * 2008-07-08 2015-05-20 ベータ・ファーマ・インコーポレイテッドＢｅｔａ Ｐｈａｒｍａ， Ｉｎｃ． 塩酸イコチニブ、合成物、結晶学的形態、併用薬及びその用途
US20120322817A1 (en) 2009-09-23 2012-12-20 Melissa Dumble Combination
AU2010298280B2 (en) 2009-09-23 2014-07-03 Novartis Ag Combination
AU2010298020B8 (en) 2009-09-28 2013-10-10 Glaxosmithkline Llc Combination
RS65800B1 (sr) * 2009-10-16 2024-08-30 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
EP2501379B1 (en) 2009-11-17 2016-03-23 Novartis AG Combination
EP2608790A4 (en) 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit

Also Published As

Publication number Publication date
SI2654736T1 (sl) 2020-10-30
TWI505828B (zh) 2015-11-01
US20140154316A1 (en) 2014-06-05
US9271941B2 (en) 2016-03-01
MX2013007073A (es) 2013-09-26
PL4159205T3 (pl) 2024-06-24
ZA201304189B (en) 2014-02-26
BR112013015602B1 (pt) 2022-03-03
AU2011349422A1 (en) 2013-05-02
US20130266649A1 (en) 2013-10-10
US8580304B2 (en) 2013-11-12
EP4159204A1 (en) 2023-04-05
DOP2013000138A (es) 2013-11-30
NZ612157A (en) 2015-05-29
EA201390913A1 (ru) 2014-04-30
PT4159205T (pt) 2024-05-08
ES2982775T3 (es) 2024-10-17
CA2822701C (en) 2018-10-23
AU2011349422B2 (en) 2015-12-10
KR20130130028A (ko) 2013-11-29
SI4159205T1 (sl) 2024-06-28
EA025198B1 (ru) 2016-11-30
TW201249441A (en) 2012-12-16
RS65497B1 (sr) 2024-06-28
DK2654736T3 (da) 2020-09-14
UA113158C2 (xx) 2016-12-26
US20140099365A1 (en) 2014-04-10
JP2014510704A (ja) 2014-05-01
CR20130352A (es) 2013-12-18
RS65496B1 (sr) 2024-06-28
LT2654736T (lt) 2020-09-25
PT4159204T (pt) 2024-05-07
MA34883B1 (fr) 2014-02-01
AR122185A2 (es) 2022-08-24
CN103998041A (zh) 2014-08-20
EP2654736A4 (en) 2015-04-22
PL2654736T3 (pl) 2020-12-14
US20140037726A1 (en) 2014-02-06
HUE050788T2 (hu) 2021-01-28
PE20140040A1 (es) 2014-02-26
JP6126014B2 (ja) 2017-05-10
IL226855A (en) 2017-04-30
JP2017137299A (ja) 2017-08-10
US9155706B2 (en) 2015-10-13
LT4159205T (lt) 2024-05-10
HUE066526T2 (hu) 2024-08-28
BR112013015602A2 (pt) 2017-02-21
HRP20240563T1 (hr) 2024-08-16
HUE066525T2 (hu) 2024-08-28
EP4159205A1 (en) 2023-04-05
PT2654736T (pt) 2020-09-24
SG191054A1 (en) 2013-08-30
MY170501A (en) 2019-08-08
EP3808343A1 (en) 2021-04-21
AR084102A1 (es) 2013-04-24
EP4159204B1 (en) 2024-02-14
HRP20240564T1 (hr) 2024-09-27
DK4159205T3 (da) 2024-05-13
US9399021B2 (en) 2016-07-26
CL2013001779A1 (es) 2014-06-27
LT4159204T (lt) 2024-05-10
ES2820536T3 (es) 2021-04-21
WO2012088033A3 (en) 2014-03-13
EP2654736A2 (en) 2013-10-30
CN103998041B (zh) 2016-08-17
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
HRP20201409T1 (hr) 2020-11-27
PL4159204T3 (pl) 2024-07-01
WO2012088033A2 (en) 2012-06-28
CA2822701A1 (en) 2012-06-28
CY1123376T1 (el) 2021-12-31
FI4159204T3 (fi) 2024-04-22
UY33818A (es) 2012-07-31
SI4159204T1 (sl) 2024-06-28
FI4159205T3 (fi) 2024-04-23
EP4159205B1 (en) 2024-02-14
KR101911109B1 (ko) 2018-10-23
US20120183613A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
JO3594B1 (ar) تركيبة صيدلانية جديدة
PH12015501168A1 (en) Novel pharmaceutical composition
IN2014KN01664A (ar)
IL219424A (en) Imidazo derivative [b – 1,2] pyridazine, combinations, distant preparations containing them and process for their preparation and use as pde10 inhibitors
SG11201405561RA (en) PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
ZA201406148B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
ZA201300002B (en) Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
IL222120A (en) Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
IL220544A (en) History of n - (h1 - indazole - 4 - ram) imidazo [2,1 - a] pyridine - 3 - carboxamide, processes for their preparation and pharmaceutical preparations containing them
IN2012DN02577A (ar)
EP2456471A4 (en) IRON-BASED PREPARATION FOR USE IN PHARMACEUTICAL PREPARATION AND PREPARATION METHOD THEREOF
IL212942A (en) History of Rifamycin, Methods of Preparation, Pharmaceutical Preparations Containing Them and Their Uses
IL217293A (en) Annotations of 9,8,7,6-tetrahydropyrimido {{a-2,1 pyramidine-4-one)
IL217759A (en) Pyrolidine derivatives as 3nk receptor antagonists, pharmaceuticals containing them, process for preparation, and use thereof for drug preparation
ZA201209674B (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
IL224683A (en) 7,6-Dihydro-h3-Oxazolo [4,3-a] pyrazine-8,5-Derivative Processes, Preparation Processes and Pharmaceutical Preparations Containing Them
IL218801A (en) Combination containing n - {3 - [3 - cyclopropyl - 5 - (2 - fluoro - 4 - iodo - phenylamino) 6,8 - dimethyl - 2, 4, 7 - trioxo - 3, 4, 6, 7 - tetrahydro - 2 h - Pyrido [4, 3 – d] pyrimidine – 1 – yl] phenyl} acetamide, and n - {(1s) –2– amino-1 - [(3-fluorophenyl) methyl] ethyl} –5-chloro-4 - (4-Chloro-1-Methyl-1H-Pyrazole-5-Yl) -2-Theophenecarboxamide
EP2863899B8 (en) Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
CO6781490A2 (es) Nueva composición farmacéutica